About: Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin. Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Oncogenic, moderately immunogenic, MHC class I- and class II-, B7(-), MK16/l/III ABC (MK16) cells were previously established by co-transfection of HPV16 E6/E7 and activated H-ras oncogene DNA into C57BL/6 kidney cells. Subcutaneous transplantation of these cells produced progressively growing local neoplasms which metastasized spontaneously to lungs and lymph nodes. The MK16 cells were implanted into syngeneic mice and used to examine whether the tumour lacking the signal molecules required for the induction of and sensitivity to T cell immunity is susceptible to local IL-2 treatment and IL-2 gene therapy. Peritumoural administration of human rIL-2 or murine IL-2 gene-modified MK16 tumour vaccine inhibited growth of subcutaneous MK16 tumour transplants and reduced the number of their lung metastases. These results indicate that experimental tumours which are MHC class I- and mimick in this respect a high proportion of human HPV16-associated carcinomas are suitable for IL-2 treatment. Oncogenic, moderately immunogenic, MHC class I- and class II-, B7(-), MK16/l/III ABC (MK16) cells were previously established by co-transfection of HPV16 E6/E7 and activated H-ras oncogene DNA into C57BL/6 kidney cells. Subcutaneous transplantation of these cells produced progressively growing local neoplasms which metastasized spontaneously to lungs and lymph nodes. The MK16 cells were implanted into syngeneic mice and used to examine whether the tumour lacking the signal molecules required for the induction of and sensitivity to T cell immunity is susceptible to local IL-2 treatment and IL-2 gene therapy. Peritumoural administration of human rIL-2 or murine IL-2 gene-modified MK16 tumour vaccine inhibited growth of subcutaneous MK16 tumour transplants and reduced the number of their lung metastases. These results indicate that experimental tumours which are MHC class I- and mimick in this respect a high proportion of human HPV16-associated carcinomas are suitable for IL-2 treatment. (en)
Title	Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin. Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin. (en)
skos:prefLabel	Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin. Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin. (en)
skos:notation	RIV/68378050:_____/02:23033173!RIV/2004/AV0/A23004/N
http://linked.open.../vavai/riv/strany	643;646
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(NC5900), Z(AV0Z5052915)
http://linked.open...iv/cisloPeriodika	20
http://linked.open...vai/riv/dodaniDat	2004
http://linked.open...aciTvurceVysledku	Mendoza, Luis Jandlová, Táňa Mikyšková, Romana Šímová, Jana Bieblová, Jana Bubeník, Jan Indrová, Marie
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Ústav molekulární genetiky AV ČR, v. v. i.
http://linked.open...dnocenehoVysledku	667496
http://linked.open...ai/riv/idVysledku	RIV/68378050:_____/02:23033173
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	HPV16, IL-2; tumour vaccines; gene therapy (en)
http://linked.open.../riv/klicoveSlovo	tumour vaccines HPV16 gene therapy IL-2
http://linked.open...odStatuVydavatele	GR - Řecká republika
http://linked.open...ontrolniKodProRIV	[121382A4A506]
http://linked.open...i/riv/nazevZdroje	International Journal of oncology
http://linked.open...in/vavai/riv/obor	EB
http://linked.open...ichTvurcuVysledku	7 (xsd:int)
http://linked.open...cetTvurcuVysledku	10 (xsd:int)
http://linked.open...ocetUcastnikuAkce	0 (xsd:int)
http://linked.open...nichUcastnikuAkce	0 (xsd:int)
http://linked.open...vavai/riv/projekt	Gene immunotherapy of tumours with different expression of MHC-I.
http://linked.open...UplatneniVysledku	2002
http://linked.open...v/svazekPeriodika	2002
http://linked.open...iv/tvurceVysledku	Bieblová, Jana Bubeník, Jan Indrová, Marie Mikyšková, Romana Šímová, Jana Šmahel, M. Jandlová, Táňa Vonka, V. Mendoza, Luis Žák, R.
http://linked.open...n/vavai/riv/zamer	Regulace a signální cesty uplatňující se v genové expresi, imunitě, onkogenezi, replikaci virů, tvorbě buněčných struktur, chování buněk, vývoji a oplození
issn	1019-6439
number of pages	4 (xsd:int)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 36 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software